NDA 020839 · Sanofi Aventis US
Plavix
Clopidogrel Bisulfate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Sep 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Nov 17, 1997
Approved uses
4
Original approval plus efficacy supplements
Registered trials
959
224 Phase 3, 102 recruiting
FAERS reports
199,047
161,504 serious, 21,942 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE See full prescribing information for complete boxed warning. Effectiveness of Plavix depends on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. ( 5.1 , 12.3 ) Tests are available to identify patients who are CYP2C19 poor metabolizers. ( 12.5 ) Consider use of another platelet P2Y 12 inhibitor in patients identified as CYP2C19 poor metabolizers. ( 5.1 ) The effectiveness of Plavix results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1) , Clinical Pharmacology (12.3) ] . Plavix at recommended doses...
What it is approved for
From the label in effect May 30, 2025.
Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) – For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke. ( 1.1 ) Recent MI, recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the rate of MI and stroke. ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Plavix is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Plavix should be administered in conjunction with aspirin. Plavix is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Plavix should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke Plavix is indicated to reduce the rate of MI and stroke.
Mechanism: Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP receptors on platelets.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 6, 2011 Supplement 51 · Efficacy · priority review LetterReviewPediatric Written Request
- Aug 17, 2006 Supplement 34 · Efficacy · priority review ReviewLetterLabel
- Feb 27, 2002 Supplement 19 · Efficacy · priority review ReviewLabelLetter
- Nov 17, 1997 Original approval · Type 1 - New Molecular Entity ReviewOther Important Information from FDA
2 products under this application
- PLAVIX · CLOPIDOGREL BISULFATE EQ 300MG BASE · TABLET, ORAL · Prescription · TE AB
- PLAVIX · CLOPIDOGREL BISULFATE EQ 75MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clopidogrel Bisulfate" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial InfarctionPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00222573 · 46,000 participants · Start Jul 1999
Drug: clopidogrel and metoprolol · For: Acute Myocardial Infarction
Sites: Beijing, China; Oxford, United Kingdom
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionSPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00335452 · 25,086 participants · Start Jun 2006 · Primary completion Sep 2009
Drug: Clopidogrel; acetylsalicyclic acid (ASA) · For: Acute Coronary Disease; Angina Unstable
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 38 sites in all
- PRoFESS - Prevention Regimen For Effectively Avoiding Second StrokesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00153062 · 20,332 participants · Start Aug 2003 · Primary completion Apr 2008
Drug: Aggrenox; Aggrenox and 10 more · For: Stroke
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 667 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- ACT-GLOBAL Adaptive Platform Trial for StrokePivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06352632 · 20,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2034
Drug: Standard-dose intravenous tenecteplase; Low-dose intravenous tenecteplase and 9 more · For: Stroke
Sites: Sydney, Australia; Calgary, Canada
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary SyndromePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00391872 · 18,624 participants · Start Oct 2006 · Primary completion Mar 2009
Drug: Ticagrelor; Clopidogrel · For: Acute Coronary Syndrome
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 672 sites in all
- GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent ImplantationPivotal-lookingCompleted
ECRI bvIndustry
NCT01813435 · 15,991 participants · Start Jul 1, 2013 · Primary completion Nov 9, 2015
Drug: Ticagrelor; Acetylsalicylic Acid and 1 more · For: Coronary Artery Disease (CAD)
Sites: Brisbane, Australia; Melbourne, Australia; Graz, Austria · 130 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea10,292
- myocardial infarction9,569
- fatigue8,828
- gastrointestinal haemorrhage8,322
- nausea8,152
- dizziness7,985
- diarrhoea7,688
- drug ineffective7,524
- asthenia6,927
- fall6,765
- cerebrovascular accident6,585
- death6,241
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,547 |
| 2005 | 3,480 |
| 2006 | 4,504 |
| 2007 | 4,198 |
| 2008 | 5,010 |
| 2009 | 6,078 |
| 2010 | 7,650 |
| 2011 | 7,642 |
| 2012 | 8,311 |
| 2013 | 7,180 |
| 2014 | 16,070 |
| 2015 | 11,834 |
| 2016 | 12,873 |
| 2017 | 11,625 |
| 2018 | 14,724 |
| 2019 | 15,471 |
| 2020 | 12,377 |
| 2021 | 9,944 |
| 2022 | 8,132 |
| 2023 | 7,597 |
| 2024 | 7,803 |
| 2025 | 8,128 |
| 2026 | 5,864 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Plavix (Clopidogrel Bisulfate)
2024 spending
$6.2M
Beneficiaries
3,054
12,338 claims
Per beneficiary
$2,033
$7.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,672,448 |
| 2021 | $7,990,526 |
| 2022 | $7,671,667 |
| 2023 | $7,228,749 |
| 2024 | $6,208,363 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Discontinuation of Plavix® (clopidogrel) for hip fracture surgery. A systematic review of the literature.
Mattesi L, Noailles T, Rosencher N, et al. · Orthop Traumatol Surg Res 2016 · Systematic Review
- Quality assessment of platelet rich plasma during anti-platelet therapy.
Smith CW, Binford RS, Holt DW, et al. · Perfusion 2007 · Clinical Trial, Research Support, Non-U.S. Gov't
- Intracoronary radiation therapy using a novel beta emitter for in-stent restenosis Tungsten WRIST.
Dilcher C, Satler LF, Pichard AD, et al. · Cardiovasc Revasc Med 2005 · Randomized Controlled Trial
- Clopidogrel generic formulations in the era of new antiplatelets: a systematic review.
Tsoumani ME, Kalantzi KI, Goudevenos IA, et al. · Curr Vasc Pharmacol 2014 · Systematic Review
- Effects of various antiplatelet drugs on ex vivo platelet activation induced by equine herpesvirus type 1.
Hernandez D, Yeo WM, Brooks MB, et al. · Am J Vet Res 2016 · Randomized Controlled Trial
- Branded versus generic clopidogrel in cardiovascular diseases: a systematic review.
Caldeira D, Fernandes RM, Costa J, et al. · J Cardiovasc Pharmacol 2013 · Comparative Study, Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.